Ossium Health, Inc.
Ossium Health is a pioneering bioengineering company dedicated to transforming cell therapy and transplantation. Their mission is to improve health, vitality, and longevity through innovative bioengineering solutions, including a deceased donor bone marrow banking platform. They focus on developing stem cell therapies for blood and immune diseases, and have recently expanded into orthopedics with the entry of OssiGraft. Ossium has achieved significant milestones such as accepting its first vertebral body donors, securing multiple rounds of funding, and forming strategic partnerships with government agencies and healthcare organizations. Their work aims to make transplants more accessible and effective, ultimately advancing the field of regenerative medicine and cellular therapeutics.
Industries
Nr. of Employees
medium (51-250)
Ossium Health, Inc.
80 Tehama St, San Francisco, CA 94105
Patents
Products
Cryopreserved deceased-donor bone marrow grafts
Characterized, cryopreserved bone marrow grafts derived from deceased donors intended for allogeneic hematopoietic cell transplantation and related clinical applications.
Viable bone matrix allograft for orthopedic use
Processed viable bone matrix allograft formulated for orthopedic and spine procedures to repair or reconstruct bone defects, provided with moldable consistency for surgical handling.
Cryopreserved deceased-donor bone marrow grafts
Characterized, cryopreserved bone marrow grafts derived from deceased donors intended for allogeneic hematopoietic cell transplantation and related clinical applications.
Viable bone matrix allograft for orthopedic use
Processed viable bone matrix allograft formulated for orthopedic and spine procedures to repair or reconstruct bone defects, provided with moldable consistency for surgical handling.
Services
Program providing clinical access to investigational banked deceased-donor marrow grafts for patients who cannot enroll in ongoing trials.
Operational services and standardized recovery protocols for procurement of vertebral bodies and marrow from deceased donors, plus onboarding and integration services for organ procurement organizations and recovery partners.
Provision of characterized, cryopreserved donor marrow grafts and associated cold-chain logistics to support clinical trial sites and transplant centers.
Contracted development and supply planning of ready-to-use cryopreserved marrow units for government and public health emergency response use cases.
Program providing clinical access to investigational banked deceased-donor marrow grafts for patients who cannot enroll in ongoing trials.
Operational services and standardized recovery protocols for procurement of vertebral bodies and marrow from deceased donors, plus onboarding and integration services for organ procurement organizations and recovery partners.
Provision of characterized, cryopreserved donor marrow grafts and associated cold-chain logistics to support clinical trial sites and transplant centers.
Contracted development and supply planning of ready-to-use cryopreserved marrow units for government and public health emergency response use cases.
Expertise Areas
- Deceased-donor bone marrow banking
- Hematopoietic stem and progenitor cell transplantation
- Cell therapy manufacturing and GMP operations
- Cryopreservation and biobanking
Key Technologies
- Bone marrow cell banking
- Cryopreservation and cryostorage systems
- GMP cleanroom manufacturing
- CD34+ cell enumeration and dosing
News & Updates
Ossium will be exhibiting at the 2025 Transplantation & Cellular Therapy (Tandem) Meetings in Honolulu, Hawaii, to showcase their latest developments including the PRESERVE I clinical trial and HOPE program.
Ossium announced a contract with BARDA to develop ready-to-use bone marrow for national emergency preparedness, initially funded at $21 million, with potential to reach $125 million.
Ossium announced positive preliminary outcomes for its first leukemia patient treated with organ donor-derived bone marrow, with successful engraftment and no adverse events.
Ossium was recognized for its company culture that encourages innovation from every corner of the organization.
Ossium will be exhibiting at the 2025 Transplantation & Cellular Therapy (Tandem) Meetings in Honolulu, Hawaii, to showcase their latest developments including the PRESERVE I clinical trial and HOPE program.
Ossium announced a contract with BARDA to develop ready-to-use bone marrow for national emergency preparedness, initially funded at $21 million, with potential to reach $125 million.
Ossium announced positive preliminary outcomes for its first leukemia patient treated with organ donor-derived bone marrow, with successful engraftment and no adverse events.
Ossium was recognized for its company culture that encourages innovation from every corner of the organization.